Matrix IntraDose
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Oncologic Drugs Advisory Committee is scheduled to review the injectable cisplatin/epinephrine gel Sept. 10 for treatment of recurrent or refractory head and neck cancer. Matrix plans a conference call after the meeting to discuss results of the review. The company hopes to launch IntraDose by January 2002. An NDA for the agent was submitted Jan. 4